Fibroid Uterus, Leiomyoma, Menorrhagia, Metrorrhagia, Uterine Fibroids
Conditions
Keywords
Symptomatic Uterine Fibroids, Excessive Uterine Bleeding, Uterine Hemorrhage, asoprisnil
Brief summary
The objective of this study is to determine the long-term safety of asoprisnil in women with symptomatic uterine fibroids who completed the 6 month Study C02-037.
Detailed description
No medical therapy is currently available for the long-term treatment of abnormal uterine bleeding associated with uterine fibroids in women and many women must resort to surgery for relief. The objective of this study is to determine the long-term safety of asoprisnil 10 and 25 mg administered daily for 18 months to subjects with symptomatic uterine leiomyomata who completed the 6 month Study C02-037. The safety endpoints for this study will be based on assessments of the endometrium, ovarian cysts, lipid profiles, adverse events and clinical laboratory evaluations. Some subjects receiving asoprisnil developed endometrial changes. As a result, dosing was prematurely discontinued for all subjects. To ensure safety, subjects will remain on study and will undergo scheduled study procedures. In most subjects, endometrial changes reversed after asoprisnil discontinuation.
Interventions
DRUGAsoprisnil
10mg Tablet, oral Daily for 18 months
Sponsors
Abbott
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women that have completed 6 months of treatment in study C02-037 with no more than a 7-day interruption in their treatment * Otherwise good health * Premenopausal based on Estrogen and Follicle Stimulating Hormone levels * Agrees to double-barrier method of contraception * Adequate endometrial biopsy with no significant histological disorder
Exclusion criteria
* Any abnormal lab or procedure result(s) the study-doctor considers important * History of a blood-clotting disorder * Any prior surgical and/or invasive procedure(s) for uterine fibroids that resulted in either a cure or made the symptoms go away * Significant gynecological disorder, such as endometrial polyp
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Long Term Safety | Throughout 18 month treatment period |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of subjects who responded positively to the Global Efficacy Questions. | Months 6, 12, 18 |
| Cumulative and incremental amenorrhea rates. | Each month 1-18 |
| Change from baseline in total symptom severity score and the Uterine Fibroid Symptoms-Quality of Life total score. | Final Visit |
| Change from baseline in menorrhagia, metrorrhagia, bloating, pelvic pressure, dysmenorrhea, pelvic pain and urinary symptoms. | Final Visit |
| Change from baseline in Uterine Fibroid Impact Questionnaire. | Months 6, 12, 18 |
| Percentage of subjects who discontinue with the intent to have surgery for fibroids. | During Treatment Period |
| Change from baseline in the two dimensions of the SF-36. | Final Visit |
| Change from baseline in the monthly bleeding score. | Final Month |
| Change from baseline in the hemoglobin concentration. | Final Visit |
| Percent change from baseline in volume of the largest fibroid. | Final Visit |
| Change from baseline in the Work Limitation Questionnaire Index. | Final Visit |
Outcome results
None listed